Free Trial

Edgewise Therapeutics (EWTX) Stock Price, News & Analysis

-0.87 (-4.79%)
(As of 05/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
426,440 shs
Average Volume
744,496 shs
Market Capitalization
$1.62 billion
P/E Ratio
Dividend Yield
Price Target

Edgewise Therapeutics MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
80.2% Upside
$31.20 Price Target
Short Interest
10.36% of Float Sold Short
Dividend Strength
News Sentiment
1.40mentions of Edgewise Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$239,495 Sold Last Quarter
Proj. Earnings Growth
From ($1.65) to ($2.04) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.70 out of 5 stars

Medical Sector

629th out of 915 stocks

Pharmaceutical Preparations Industry

298th out of 426 stocks

EWTX stock logo

About Edgewise Therapeutics Stock (NASDAQ:EWTX)

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

EWTX Stock Price History

EWTX Stock News Headlines

Edgewise Therapeutics (NASDAQ:EWTX) Shares Down 3.7%
JANX Janux Therapeutics, Inc.
Edgewise Therapeutics: Q4 Earnings Insights
Edgewise Therapeutics Non-GAAP EPS of $0.47
See More Headlines
Receive EWTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edgewise Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
5 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$5.73 per share


Free Float
Market Cap
$1.62 billion
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Peter A. Thompson FACP (Age 64)
    M.D., Co-Founder & Independent Chairman
    Comp: $76k
  • Dr. Kevin Koch Ph.D. (Age 64)
    President, CEO & Director
    Comp: $905.52k
  • Dr. Badreddin Edris Ph.D. (Age 37)
    Co-Founder & Independent Director
    Comp: $43k
  • Dr. Behrad Derakhshan Ph.D. (Age 44)
    Chief Business Officer
    Comp: $630.67k
  • Dr. Joanne M. Donovan M.D. (Age 67)
    Ph.D., Chief Medical Officer
    Comp: $696.4k
  • Dr. Alan J. Russell Ph.D. (Age 54)
    Co-Founder, Chief Scientific Officer & Director
    Comp: $657.52k
  • Mr. R. Michael Carruthers (Age 66)
    Chief Financial Officer
    Comp: $386.01k
  • Mr. John R. Moore (Age 60)
    General Counsel
  • Dr. Marc Semigran M.D. (Age 67)
    Chief Development Officer

EWTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Edgewise Therapeutics stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edgewise Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EWTX shares.
View EWTX analyst ratings
or view top-rated stocks.

What is Edgewise Therapeutics' stock price target for 2024?

5 equities research analysts have issued 1-year target prices for Edgewise Therapeutics' shares. Their EWTX share price targets range from $25.00 to $48.00. On average, they predict the company's share price to reach $31.20 in the next twelve months. This suggests a possible upside of 80.2% from the stock's current price.
View analysts price targets for EWTX
or view top-rated stocks among Wall Street analysts.

How have EWTX shares performed in 2024?

Edgewise Therapeutics' stock was trading at $10.94 at the beginning of the year. Since then, EWTX shares have increased by 58.2% and is now trading at $17.31.
View the best growth stocks for 2024 here

When is Edgewise Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our EWTX earnings forecast

How were Edgewise Therapeutics' earnings last quarter?

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.05.

What ETFs hold Edgewise Therapeutics' stock?

ETFs with the largest weight of Edgewise Therapeutics (NASDAQ:EWTX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) and ALPS Medical Breakthroughs ETF (SBIO).iShares U.S. Pharmaceuticals ETF (IHE).

When did Edgewise Therapeutics IPO?

Edgewise Therapeutics (EWTX) raised $150 million in an IPO on Friday, March 26th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, SVB Leerink and Wedbush PacGrow served as the underwriters for the IPO.

Who are Edgewise Therapeutics' major shareholders?

Edgewise Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (9.54%), Baker BROS. Advisors LP (6.25%), Vanguard Group Inc. (4.31%), Janus Henderson Group PLC (1.93%), Artal Group S.A. (0.87%) and Kennedy Capital Management LLC (0.31%). Insiders that own company stock include Alan J Russell, Behrad Derakhshan, Holdings A/S Novo, Joanne M Donovan, John R Moore, Jonathan C Fox, Kevin Koch, Orbimed Advisors Llc, Peter A Thompson and R Michael Carruthers.
View institutional ownership trends

How do I buy shares of Edgewise Therapeutics?

Shares of EWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EWTX) was last updated on 5/24/2024 by Staff

From Our Partners